ReviewCurrent opinion in virology2014
Immune response to HHV-6 and implications for immunotherapy.
Review in Current opinion in virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- Impact of cellular proteases on the function of antiviral antibodies.Journal of virology · 2026Review
- Human herpesvirus reactivation and its potential role in the pathogenesis of post-acute sequelae of SARS-CoV-2 infection.GeroScience · 2025Review
- Human herpesvirus 6-specific T-cell immunity in allogeneic hematopoietic stem cell transplant recipients.Blood advances · 2023Observational
- The Spectrum of Neurological Manifestations of Human Herpesvirus 6 Infection in Children.Cureus · 2021Article
- Human Herpesvirus-6 and -7 in the Brain Microenvironment of Persons with Neurological Pathology and Healthy People.International journal of molecular sciences · 2021Article
- Targeting Host Cellular Factors as a Strategy of Therapeutic Intervention for Herpesvirus Infections.Frontiers in cellular and infection microbiology · 2021Review
- Review
- Review
- Pathogen-Specific T Cells Beyond CMV, EBV and Adenovirus.Current hematologic malignancy reports · 2019Review
- Phenotypic and Functional Differences between Human Herpesvirus 6- and Human Cytomegalovirus-Specific T Cells.Journal of virology · 2019Article
- Identification of CD4 and H-2KScientific reports · 2019Article
- Cross-sectional analysis of CD8 T cell immunity to human herpesvirus 6B.PLoS pathogens · 2018Article
- Advances in the Characterization of the T-Cell Response to Human Herpesvirus-6.Frontiers in immunology · 2018Review
- CD8Journal of immunology (Baltimore, Md. : 1950) · 2017Article
- Serological evidence that activation of ubiquitous human herpesvirus-6 (HHV-6) plays a role in chronic idiopathic/spontaneous urticaria (CIU).Clinical and experimental immunology · 2016Review
- Human herpesvirus-6 encephalitis after allogeneic hematopoietic cell transplantation: what we do and do not know.Bone marrow transplantation · 2015Review
- Laboratory and clinical aspects of human herpesvirus 6 infections.Clinical microbiology reviews · 2015Review
- Article
- Encephalopathy Post CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Beyond ICANS.Journal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Most adults remain chronically infected with HHV-6 after resolution of a primary infection in childhood, with the latent virus held in check by the immune system. Iatrogenic immunosuppression following solid organ transplantation (SOT) or hematopoetic stem cell transplantation (HSCT) can allow latent viruses to reactivate. HHV-6 reactivation has been associated with increased morbidity, graft rejection, and neurological complications post-transplantation. Recent work has identified HHV-6 antigens that are targeted by the CD4+ and CD8+ T cell response in chronically infected adults. T cell populations recognizing these targets can be expanded in vitro and are being developed for use in autologous immunotherapy to control post-transplantation HHV-6 reaction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.